Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q1 GAAP EPS results and issued a year-over-year decrease in Q1 sales results.
Portfolio Pulse from Benzinga Newsdesk
Protalix BioTherapeutics shares dropped following a report of worse-than-expected Q1 GAAP EPS results and a year-over-year decrease in Q1 sales.
May 10, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Protalix BioTherapeutics reported lower than expected Q1 GAAP EPS and a decrease in sales compared to last year, leading to a decline in share price.
The negative earnings report and sales decrease directly impact investor sentiment and the perceived value of Protalix BioTherapeutics, likely leading to a short-term decline in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100